Claim OwnershipMedical Digest & Congress Report
Subscribed: 65Played: 603
Subscribe
© Medical Congress News
Description
The MedicalDigest.org / CongressReport.eu podcast covers the latest evidence based medical news from cardiology, hematology, oncology, diabetology, pulmonology, dermatology, urology and more. Made for healthcare professionals and researchers, we are an independent, open-access platform. CongressReport.eu portal enables HCPs to get acquainted with new clinical trial results, medical diagnostic and treatment guidelines. Our non-promotional website collects and stores the relevant scientific information, KOL insights, key lectures, poster presentations in a user-friendly format.
795 Episodes
Reverse
Professor Domenica Lorusso explores the latest therapeutic advances and emerging strategies for managing platinum-resistant ovarian cancer after the ESMO Congress 2026.Video: https://medicaldigest.org/scientific-contents/interview:recent-advances-treatment-platinum-resistant-ovarian-cancer
Doctor Brian M. Slomovitz presents Phase 3 KEYNOTE-C93/GOG-3064/ENGOT-en15 data evaluating first-line pembrolizumab monotherapy versus carboplatin plus paclitaxel in mismatch repair-deficient (dMMR) advanced or recurrent endometrial carcinoma at the ESMO Congress 2026.Video: https://medicaldigest.org/scientific-contents/interview:keynote-c93-first-line-pembrolizumab-vs-chemotherapy-dmmr-advanced-or-recurrent-endometrial-carcinoma
Doctor Hope S. Rugo presents results from the Phase 3 KEYNOTE-B49 study evaluating pembrolizumab versus placebo in combination with chemotherapy in patients with HR+/HER2− advanced breast cancer at the ESMO Congress 2026.Video: https://medicaldigest.org/scientific-contents/interview:keynote-b49-pembrolizumab-plus-chemotherapy-hrher2-advanced-breast-cancer
Professor Hope S. Rugo discusses key advances, targeted systemic options, and novel treatment strategies in managing brain metastases in patients with metastatic breast cancer at the ESMO Congress 2026.Video: https://medicaldigest.org/scientific-contents/interview:advances-brain-metastases-management-breast-cancer
Doctor Jacob Sands presents primary analysis data from the Phase 3 DeLLphi-305 trial, evaluating tarlatamab plus durvalumab versus durvalumab alone as first-line maintenance therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) at the ESMO Congress 2026.Video: https://medicaldigest.org/scientific-contents/interview:available-research-guiding-selection-therapy-patients-chronic-lymphocytic-leukemia
Comments
Download from Google Play
Download from App Store
United States